CTLA4 and neoplasm: Longitudinal BLI indicated significant delay of tumor growth in mice receiving combined IL-6 and CTLA-4 blockade as compared with isotype control (p=0.002) or single agent (Figure 2B; P = 0.017 versus α–IL-6; P = 0.09 versus α–CTLA-4).